About
Bio
Circulation:The publisher does not disclose the circulationAims of the Journal:DTB articles aim to provide healthcare professionals with practical and impartial advice on treatment. The way DTB produces articles has been gradually refined since it started in 1962, but the essential principles have remained unchanged.DTB's main aims are: to provide informed and unbiased assessments of drugs and other treatments (focusing on efficacy, safety, convenience and cost in particular in relation to other available treatments); to comment on how those drugs or other treatments should be used; to assess their place in overall management, and; to review evidence and give practical advice on the overall management of disease.Over the years, DTB has initiated successful campaigns for the removal or restriction of medicines that it could not recommend, prompted withdrawal of excessive promotional claims and exposed fundamental weaknesses in certain prescribing practice. The journal claims that surveys of their readership have consistently shown that readers find DTB authoritative and influential in relation to their decisions, recommendations or advice on treatments.Content:DTB provides articles based on a synthesis of evidence with opinions from a wide range of specialist and generalist commentators, typically over 40 individuals and organisations for each article. It is aimed at doctors, pharmacists and other healthcare professionalsDTB topics include:Healthy dietsLevonogestrel IUSOsteoporosisAlprostadil creamLurasidoneDrug ShortagesPrescription ChargesOlodaterolEditorial contacts:Editor in Chief dtbeditor@bmj.comProduction Editor production.dtb@bmj.comOther information:Most articles start as a draft commissioned by one of our editorial team and written by an 'outside' expert. But the finished article is the result of detailed scrutiny, collaboration and revision involving a wide range of commentators and several editing stages. The resulting article, no longer attributable to any one source, is published unsigned and represents the view of DTB. It is not simply a distillation of the opinions of the commentators.Information on advertising can be found hereBest way to contact the Editor is by email.
Email
email@cision.one
Website
site@cision.one
Social media
Location
United Kingdom
Frequency
upgrade
Circulation
upgrade
Sectors
Doctors, Nurses & Health Providers, Medicine, Pharmaceuticals
Bio
Circulation:The publisher does not disclose the circulationAims of the Journal:DTB articles aim to provide healthcare professionals with practical and impartial advice on treatment. The way DTB produces articles has been gradually refined since it started in 1962, but the essential principles have remained unchanged.DTB's main aims are: to provide informed and unbiased assessments of drugs and other treatments (focusing on efficacy, safety, convenience and cost in particular in relation to other available treatments); to comment on how those drugs or other treatments should be used; to assess their place in overall management, and; to review evidence and give practical advice on the overall management of disease.Over the years, DTB has initiated successful campaigns for the removal or restriction of medicines that it could not recommend, prompted withdrawal of excessive promotional claims and exposed fundamental weaknesses in certain prescribing practice. The journal claims that surveys of their readership have consistently shown that readers find DTB authoritative and influential in relation to their decisions, recommendations or advice on treatments.Content:DTB provides articles based on a synthesis of evidence with opinions from a wide range of specialist and generalist commentators, typically over 40 individuals and organisations for each article. It is aimed at doctors, pharmacists and other healthcare professionalsDTB topics include:Healthy dietsLevonogestrel IUSOsteoporosisAlprostadil creamLurasidoneDrug ShortagesPrescription ChargesOlodaterolEditorial contacts:Editor in Chief dtbeditor@bmj.comProduction Editor production.dtb@bmj.comOther information:Most articles start as a draft commissioned by one of our editorial team and written by an 'outside' expert. But the finished article is the result of detailed scrutiny, collaboration and revision involving a wide range of commentators and several editing stages. The resulting article, no longer attributable to any one source, is published unsigned and represents the view of DTB. It is not simply a distillation of the opinions of the commentators.Information on advertising can be found hereBest way to contact the Editor is by email.
Website
Social media
Location
Frequency
Circulation
Sectors
Doctors, Nurses & Health Providers, Medicine, Pharmaceuticals
Most recent articles by Drug and Therapeutics Bulletin
Lorem ipsum dolor sit amet, consectetur adipiscing elit
Article description
Lorem ipsum dolor sit amet, consectetur adipiscing elit
Article description
Lorem ipsum dolor sit amet, consectetur adipiscing elit
Article description
Explore outlets similar to Drug and Therapeutics Bulletin
-
Science
Founded in 1880, with seed money from Thomas Edison, Science continues to be at the center of the very best in research across the sciences, with articles that consistently rank among the most cited in the world. Science articles are peer-reviewed, and written to appeal to both scientist and layman. Regular issue features include a news and comment section, book reviews, and coverage of scientific meetings and seminars. The News section features late-breaking news and in-depth news analysis. Compass, an opinion section, publishes letters and commentary by scientists on current science issues. The TechSight section focuses on leading edge techniques and technologies. Topics include: bioinformatics, genome sequencing, and protein sequencing. This section is published in the third issue every month. The Research section features original investigative research and reporting. Other departments include NetWatch, This Week in Science, ScienceScope, Random Samples and New Products.
ViewSSTAT NewsSTAT News covers health, medicine and life science news. In specific it offers coverage on the business of making medicines, health tech, science, and public health.
ViewMedscapeMedscape was created for medical specialists, primary care physicians, and health professionals and offers medical news, clinical trial information, review articles, journal commentary, expert columns, patient education articles and book reviews. It also includes Web-based services for verifying insurance information, Medline and other search engines, as well as a physician directory enabling users to find physicians by practice, location or specialty.
ViewThe BMJThe British Medical Journal publishes papers on research, education, news & views and campaigns provided they have not been published elsewhere and/or do not overlap substantially with other published material. Papers include research, randomised controlled trials on open peer review, peer review training guidelines and clinical trials results. The British Medical Journal is published on behalf of the British Medical Association. The journal is distributed to hospital clinicians, GPs, academics and an international audience. Impact Factor: 20.7 Journal ranking: 375 (Scimago Journal & Country Rank) Manuscript Submission: Author guidlines: www.bmj.com/about-bmj/resources-authors
ViewJAMAEstablished in 1883 and published as an international, peer-reviewed, general medical journal distributed to readers in more than 148 countries. Covers all subjects that relate to the practice of medicine and the betterment of public health worldwide. Editorial content contains original contributions covering randomized controlled trials, intervention studies, studies of screening and diagnostic tests, outcome studies, case control series and surveys with high response rates. Includes systematic, critical assessments of literature and data sources pertaining to clinical topics, brief reports of original studies or evaluation and letters discussing recent articles. Also includes book, journal and new media reviews, as well as editorials, abstracts and reference directories.
ViewUse CisionOne to find more relevant outletsContact Drug and Therapeutics Bulletin and get access to over 850K accurate, up-to-date media profiles.
Discover the stories that impact your brand. In realtime.
CisionOne delivers relevant news, trends and conversations that matter to your brand with the world’s most comprehensive media monitoring service across Print, Online, TV, Radio, Social, Magazines, Podcasts and more.